ANIP (ANI Pharmaceuticals) Shiller PE Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIP ANI Pharmaceuticals Inc ANIP
87 GF Score
Price $72.81
GF Value $98.53
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ANI Pharmaceuticals  (NAS:ANIP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ANI Pharmaceuticals Shiller PE Ratio Related Terms


ANI Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Shiller PE Ratio Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANI Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIP vs ETON, ALVO, XERS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Shiller PE Ratio falls into.


ANIP
87GF Score
ANI Pharmaceuticals Inc ANIP
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ANI Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, ANI Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.052/333.9520*333.9520
=1.052

Current CPI (Jun. 2026) = 333.9520.

ANI Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 0.220 241.428 0.304
201612 -0.090 241.432 -0.124
201703 0.100 243.801 0.137
201706 0.230 244.955 0.314
201709 0.400 246.819 0.541
201712 -0.830 246.524 -1.124
201803 0.191 249.554 0.256
201806 0.233 251.989 0.309
201809 0.422 252.439 0.559
201812 0.456 251.233 0.607
201903 0.037 254.202 0.049
201906 0.528 256.143 0.689
201909 0.317 256.759 0.412
201912 -0.393 256.974 -0.511
202003 -0.589 258.115 -0.762
202006 -1.031 257.797 -1.335
202009 0.035 260.280 0.045
202012 -0.303 260.474 -0.388
202103 0.007 264.877 0.009
202106 -1.167 271.696 -1.435
202109 -0.367 274.310 -0.447
202112 -1.717 278.802 -2.056
202203 -1.273 287.504 -1.478
202206 -0.942 296.311 -1.062
202209 -0.552 296.808 -0.622
202212 -0.285 296.797 -0.320
202303 0.063 301.836 0.069
202306 0.327 305.109 0.358
202309 0.499 307.789 0.541
202312 0.039 306.746 0.042
202403 0.825 312.332 0.882
202406 -0.139 314.175 -0.148
202409 -1.266 315.301 -1.341
202412 -0.549 315.605 -0.581
202503 0.686 319.799 0.716
202506 0.361 322.561 0.374
202509 1.133 324.800 1.165
202512 1.172 324.054 1.207
202603 1.276 330.213 1.290
202606 1.052 333.952 1.052

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of $72.81 is trading 26.1% below its estimated GF Value™ of $98.53. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ANIP:

  • Shiller PE Ratio:
  • GF Value™: $98.53 vs. price of $72.81 (26.1% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ANI Pharmaceuticals Business Description

Other Exchanges BSFA:Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
87GF Score

Get the complete analysis for ANIP

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.81
Price
$98.53
GF Value